ACLX stock icon

Arcellx
ACLX

$62.43
6.55%
 

About: Arcellx Inc is a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases.

Employees: 130

0
Funds holding %
of 6,702 funds
0
Analysts bullish %
of 16 analysts
News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

153% more first-time investments, than exits

New positions opened: 38 | Existing positions closed: 15

26% more capital invested

Capital invested by funds: $2.59B [Q4 2023] → $3.27B (+$673M) [Q1 2024]

19% more repeat investments, than reductions

Existing positions increased: 69 | Existing positions reduced: 58

15% more funds holding

Funds holding: 156 [Q4 2023] → 179 (+23) [Q1 2024]

7.0% less ownership

Funds ownership: 95.99% [Q4 2023] → 88.99% (-7.0%) [Q1 2024]

10% less funds holding in top 10

Funds holding in top 10: 10 [Q4 2023] → 9 (-1) [Q1 2024]

58% less call options, than puts

Call options by funds: $5.55M | Put options by funds: $13.1M

Research analyst outlook

16 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$70
12%
upside
Avg. target
$80
29%
upside
High target
$87
39%
upside

16 analyst ratings

16 positive
100%
neutral
0%
negative
0%
Truist Securities
Asthika Goonewardene
39%upside
$87
Buy
Maintained
18 Jun 2024
Piper Sandler
Biren Amin
12%upside
$70
Overweight
Initiated
31 May 2024
Stifel
Benjamin Burnett
33%upside
$83
Buy
Maintained
15 May 2024
Evercore ISI Group
Cory Kasimov
36%upside
$85
Outperform
Initiated
14 May 2024
HC Wainwright & Co.
Emily Bodnar
28%upside
$80
Buy
Maintained
13 May 2024

Financial journalist opinion